Abstract:Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitor resistance that presents a significant clinical challenge. Herein, a series of pyrazole-3-amine derivatives were synthesized and optimized to overcome the common secondary resistance mutations of FLT3. The structure–activity relationship and molecular dynamics simulation studies illustrated that the ribose region of FLT3 could be occupied to help address the obstacle of secondary mutations. Among those derivatives, compound 67 exhibited potent and selective inhibitory activities against FLT3-ITD-positive acute myeloid leukemia (AML) cells and possessed equivalent potency against transformed BaF3 cells with a variety of secondary mutations. Besides, cellular mechanism assays demonstrated that 67 strongly inhibited phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis in MV4-11 cells. In the MV4-11 xenograft models, 67 exhibited potent antitumor potency without obvious toxicity. Taken together, these results demonstrated that 67 might be a drug candidate for the treatment of FLT3-ITD-positive AML.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01196.Molecular formula strings (CSV)FLT3 homology (PDB)Molecular modeling information involved in compound Lu-46 with FLT3-WT (PDB)Molecular modeling information involved in compound Lu-46 with FLT3-F691L (PDB)Molecular modeling information involved in compound 31 with FLT3-WT (PDB)Molecular modeling information involved in compound 31 with FLT3-F691L (PDB)Molecular modeling information involved in compound 41 with FLT3-WT (PDB)Molecular modeling information involved in compound 55 with FLT3-WT (PDB)Molecular modeling information involved in compound 55 with FLT3-F691L (PDB)Molecular modeling information involved in compound 67 with FLT3-WT (PDB)Molecular modeling information involved in compound 67 with FLT3-F691L (PDB)Molecular modeling information involved in compound 67 with FLT3-D835V (PDB)Molecular modeling information involved in compound 67 with FLT3-Y842H (PDB)Molecular modeling information involved in compound 67 with FLT3-N676D (PDB)Figures for the manuscript (ZIP)Average root-mean-square deviation (rmsd) of backbone atoms of various FLT3 protein models and compound 55 throughout MD simulations; halogen bond analysis of 55 bound to FLT3-WT and FLT3-F691L models during MD simulations (40–50 ns); cell viability of HCD57, HCD57-FLT3-ITD, and HCD57-FLT3-D835Y cells after treating with compound 67; average rmsd of backbone atoms of various FLT3 protein models and compound 67 throughout the MD simulations; halogen bond analysis of 67 bound to various FLT3 models during MD simulations (90–100 ns); apoptosis induction and cell cycle arrest effects of compound 67 on HCD57, HCD-FLT3-ITD, and HCD-FLT3-D835Y cells at 100 nM concentration; peripheral blood counts of MV4-11 xenograft tumor mice treated with compound 67; and 1H NMR and 13C NMR spectra for target compound molecular formula strings (PDF)This article has not yet been cited by other publications.

Novel Inhibitor of Flt3 Kinase and Use Thereof

NEW PI3K KINASE INHIBITOR

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Novel BCR-ABL kinase inhibitor

Design, Synthesis, and Evaluation of Pyrido.[3,4-B]pyrazin-2(1h)-one Derivatives As Potent FLT3 Inhibitors

Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.

Kinase inhibitor with novel structure

Design, synthesis, and biological evaluation of a series of indolone derivatives as novel FLT3 inhibitors for the treatment of acute myeloid leukemia

Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.

Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors

Discover Novel Covalent Inhibitors Targeting FLT3 Through Hybrid Virtual Screening Strategy.

Identification of furo[2,3-d]pyrimidin-4-ylsulfanyl-1,3,4-thiadiazole derivatives as novel FLT3-ITD inhibitors

Selective c-kit kinase inhibitor

Identification of 2-Aminopyrimidine Derivatives As FLT3 Kinase Inhibitors with High Selectivity over C-Kit.

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

Discovery of 1-(4-(4-amino-3-(4-(2-morpholinoethoxy)phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) As a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML.

Application of triciribine and/or triciribine metabolites to treatment of acute leukemia carrying FLT3 mutation genes

Abstract 4009: Discovery of PLM-102, a highly potent 3rd generation FLT3 inhibitor, in drug-resistant FLT3-ITD-TKD mutated acute myeloid leukemia

A novel azaindole-2-ones inhibitors and antitumor activity fgfr1